Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 4.53M shares, a 2594.64% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 64.00K shares, a 8.47% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 118.00K shares, a 50.21% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 214.00K shares, a 435.00% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 559.00K shares, a 54.42% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 362.00K shares, a 35.70% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 563.00K shares, a 631.17% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 77.00K shares, a 97.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 4.53M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 4.92M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 64.00K shares 10-Q · filed 2026-05-07 | 564.00K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 118.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 559.00K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 214.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 678.00K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 168.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 504.00K shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 59.00K shares 10-Q · filed 2025-05-12 | 415.00K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 237.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 362.00K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 130.00K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 79.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 286.00K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 6.00K shares 10-Q · filed 2024-05-02 | 250.00K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 563.00K shares 10-K · filed 2024-02-15 |
| 2023-09-30 | 196.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 558.00K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 43.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 362.00K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 319.00K shares 10-Q · filed 2023-05-04 | 342.00K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 77.00K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2022-06-30 | 23.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | |
| 2022-03-31 | 54.00K shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 3.24M shares 10-K · filed 2022-02-28 | |
| 2020-12-31 | 1.59M shares 10-K · filed 2022-02-28 | |
| 2019-12-31 | 3.58M shares 10-K · filed 2022-02-28 | |
| 2018-12-31 | 276.00K shares 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |